Crossmark

Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer

Crossref DOI link: https://doi.org/10.1007/s00280-016-3027-5

Published Online: 2016-04-08

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Farhat, Fadi

Kattan, Joseph G.

Ghosn, Marwan
Funding

Funding for this research was provided by:

Pierre Fabre Médicament
License Information

Text and Data Mining valid from 2016-04-08